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52 The Journal of Thoracic and Cardiobjectives: Empiric chemotherapy for patients with non–small cell lung cancer who
ave undergone resection is recommended without knowledge of the tumor’s
pecific biologic characteristics, and many patients may not benefit. In vitro che-
otherapy resistance is associated with clinical unresponsiveness in some tumors,
nd in lung cancer, chemotherapy resistance is prevalent. Multiple-agent chemo-
herapy resistance and association of chemotherapy resistance with molecular mark-
rs are described.
ethods: Chemotherapy resistance to doublets—carboplatin and paclitaxel, cispla-
in and navelbline, cisplatin and docetaxel, and cisplatin and gemcitabine—was
nalyzed in 4571 non–small cell lung cancer tumors with the extreme drug resis-
ance assay. Chemotherapy resistance is defined as follows: extreme drug resistance,
SD above the median chemotherapy resistance; intermediate drug resistance,
etween the median and extreme drug resistances; and low drug resistance, 1 SD
elow the median. Chemotherapy resistance was compared with DNA ploidy
easured by flow cytometry, and markers p53 and epithelial growth factor receptor
ere assayed by immunohistochemistry.
esults: Tumors with extreme or intermediate drug resistance were noted in 30%
o carboplatin-paclitaxel, in 24% to cisplatin-navelbline, in 42% to cisplatin-
emcitabine, and in 27% to cisplatin-docetaxel. Extreme or intermediate drug
esistance to at least one drug occurred in 74% to carboplatin-paclitaxel, in 68% to
isplatin-navelbline, in 88% to cisplatin-gemcitabine, and in 68% to cisplatin-
ocetaxel. More intermediate plus extreme chemotherapy resistances occurred in
neuploid tumors to etoposide (53% vs 36%, P  .0002) and topotecan (48% vs
6%, P  .0094), with less intermediate or extreme chemotherapy resistance to
emcitabine (88% vs 81%, P  .0345). p53-Positive tumors had more intermediate
r extreme resistance to etoposide (57% vs 44%, P  .0009) and doxorubicin (73%
s. 58%, P  .0324) and less intermediate or extreme resistance to cisplatin (44%
s 54%, P .0125), to carboplatin (47% vs 57%, P .0129), to taxol (47% vs 57%,
 .0056), and to gemcitabine (78% vs 87%, P  .0108). Fewer epithelial growth
actor receptor–positive tumors were extremely drug resistant to cisplatin (13% vs
6%, P  .0074) and carboplatin (13% v. 30%, P  .0008).
onclusions: Multi-drug chemotherapy resistance in non–small cell lung cancer
umor cultures is common, and associations between molecular markers and in vitro
hemotherapy resistance are noted. Clinical validation through integration of such
esting into clinical trials seems warranted.
ung cancer is the most common cause of cancer-related mortality. It will
account for an estimated 162,460 deaths in 2006, and approximately 174,470
new cases were expected this year. Although surgical therapy remains therimary treatment for resectable disease, the composite 5-year survival is only
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TS0%.1 Platinum-based adjuvant chemotherapy, which has
een reported to improve survival (4%–15%) for some
atients with early-stage non–small cell lung cancer
NSCLC), is now recommended for those with good per-
ormance status and completely resected stage IB-IIIA dis-
ase,2-5 yet only one study3 showed benefit for patients with
tage IB disease. Accordingly, the majority of patients en-
ure a predictable toxicity from empiric chemotherapy
ithout a survival advantage.
In contrast to targeted therapeutic agents, such as trastu-
umab inhibition of epithelial growth factor receptor
EGFR), which may hold promise toward patient-tumor
pecific treatment,6 empiric platinum-based chemotherapy
egimens represent a “hit or miss” approach in hopes for a
herapeutic benefit despite the calculable risk of significant
oxicity.
By avoiding a particular drug by testing a specific tu-
or’s phenotypic chemotherapy resistance, unnecessary
oxicity may be avoided. In vitro chemotherapy resistance
esting of fresh human tumor cells may accurately (90%)
redict that an agent may be ineffective, whereas chemo-
herapy sensitivity testing is less accurate (60%) largely
ecause it is impossible to predict the impact of important
ost and tumor biologic determinants affecting a drug’s
linical efficacy.7 For some solid tumors,8-10 clinical unre-
ponsiveness to antineoplastic agents correlates with in vitro
hemotherapy resistance, yet little correlative data exist for
SCLC.
Recently, the prevalence of chemotherapy resistance in
esected NSCLC tumor cultures to several individual anti-
eoplastic drugs was reported.11 In an effort to further
haracterize in vitro chemotherapy resistance patterns in
SCLC, agents used clinically as platinum-based doublets
ere analyzed for simultaneous in vitro 2-drug resistance,
nd the association of chemotherapy resistance in NSCLC
Abbreviations and Acronyms
ANITA  Adjuvant Navelbine International Trialist
Association trial
ASCO  American Association of Clinical Oncology
CALGB The Cancer and Leukemia Group B
ECOG  Eastern Cooperative Oncology Group
EDR  extreme drug resistant
EGFR  epithelial growth factor receptor
IALT  International Adjuvant Lung Cancer Trial
IDR  intermediate drug resistant
LDR  low drug resistant
MDR1 multiple drug resistance
NSCLC  non–small cell lung cancer
PCI  percent colony inhibitionas compared with DNA ploidy and examined for correla- s
The Journal of Thoracicions with molecular markers that may act as surrogates to
redict tumor chemotherapy resistance.
aterials and Methods
SCLC Specimens
etween September 1989 and November 2005, 4571 fresh NSCLC
umor surgical biopsy specimens from 409 institutions were ana-
yzed for chemotherapy resistance testing by Oncotech, Inc, Tus-
in, California. Since 1989, evaluability of submitted specimens
veraged 81% (range 60%–90%). The submitting institution de-
ermined tumor histologic type. Information regarding tumor his-
ologic subtype, stage, and prior chemotherapy were not routinely
eported for all specimens. From the tumor database, queries were
erformed to determine the prevalence of chemotherapy resistance
o antineoplastic agents commonly used in the treatment of
SCLC and to determine whether any correlations existed be-
ween chemotherapy resistance patterns and DNA ploidy. For
atient NSCLC tumors with known adenocarcinoma histology, the
olecular markers p53 and EGFR were evaluated. All patient
dentifiers are dissociated from this database, and per institutional
eview board approval, patient consent was waived.
he Extreme Drug Resistant (EDR) Assay
resh tumor specimens are mechanically and enzymatically dis-
ggregated into single cells and small cellular aggregates and
ultured in a cellular proliferation assay described previously in
etail.7 Tumor cultures were exposed to single chemotherapeutic
gents: cisplatin, carboplatin, etoposide, doxorubicin, topotecan,
aclitaxel, docetaxel, vinorelbine, or gemcitabine in duplicate or
riplicate assays at final concentrations 5 to 10 times higher than
xpected in vivo peak plasma levels. After a 72-hour exposure, 5
Ci of 3H-thymidine (Amersham Biosciences, Piscataway, NJ) is
dded and incubation is continued for an additional 48 hours. Cell
uspensions are harvested and cellular proliferation is determined
y 3H-thymidine incorporation into DNA and measured by scin-
illation counting (Beckman-Coulter, Inc, Fullerton, Calif). Posi-
ive controls (supralethal cisplatin resulting in 100% cell death)
repared in duplicate and negative controls (media exposed only)
repared in quadruplicate are used to determine the percent colony
nhibition (PCI) by an individual drug compared with media-
xposed cultures correcting for positive controls.
From a historical database of over 140,000 human tumors of
aried histologic type submitted for the EDR assay, the PCI values
re compared with the median PCI of the entire population for any
iven drug tested. Tumors exhibiting PCI values 1 SD above the
opulation median are defined as low drug resistant (LDR); tumors
ith PCI values between the population median and 1 SD below
he median are defined as intermediate drug resistant (IDR); and
umors with PCI values that are 1 SD below the median PCI are
efined as EDR.
NA Ploidy and S-phase Analyses by Flow Cytometry
nalyses were performed on nuclear suspensions prepared from
resh tissue as described12 using a Becton-Dickenson FACScan
ow cytometer (Becton-Dickinson, Franklin Lakes, NJ) with DNA
ell cycle and S-phase parameters programmed with ModFit LT
oftware (Variety Software House, Inc, Topsham, Maine).
































































































rom paraffin-embedded tissue sections, both mutant and wild-
ype isoforms of p53 were detected with the DO-1 monoclonal
ntibody (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif) fol-
owed by automated immunostaining on a Ventana Benchmark
Vantana Medical Systems, Inc, Tucson, Ariz) or the BioGenex
6000 (BioGenix, Inc, San Ramon, Calif) instrument. The 3,3=-
iaminobenzidine/horse radish peroxidase reagent (Genetex, Inc,
an Antonio, Tex) was used for secondary detection. Positive
taining was defined as more than 20% of cells exhibiting nuclear
taining.13
Automated measurement of EGFR expression was detected
ith the 31G7 monoclonal antibody (Invitrogen Corp, Carlsbad,
alif) after antigen retrieval with 0.25% trypsin. Positive staining
as defined by calculating the histoscore, which equals the product
f the percent EGFR positive cells times the staining intensity
cored on a scale from zero (no staining) to 3 (intense staining) as
escribed.14 An EGFR histoscore of 120 or more is considered
ositive.
tatistical Analysis
atient tumor cultures were tested against a panel between 3 and 9
ndividual drugs. From cultures tested with agents used in the 4
linically relevant platinum-based doublets—carboplatin plus
axol; cisplatin plus navelbine; cisplatin plus docetaxel; or cisplatin
lus gemcitabine—concordant resistance patterns were deter-
ined by plotting PCI values for individual tumors tested with the
rst drug (ordinate) versus the same tumor tested against the
econd drug (abscissa). Assuming that some frequency of EDR,
DR, and LDR to any given drug exist in a population of separate
umors tested against 1 drug, if a set of tumors is tested against 2
ndependent drugs, then a 3  3 matrix can be created in which 9
ossible resistance patterns are possible for the population. Within
his population, each tumor has a unique resistance to each agent;
or example, one subset of tumors will be EDR to both drugs and
subset will be LDR to both drugs. Seven other combinations of
DR, IDR, and LDR are possible. From this matrix, subpopula-
ions exhibiting any EDR plus IDR combination to both drugs
ested and those exhibiting EDR or IDR to at least one agent were
alculated. Correlation coefficients from scatter plot analysis using
inear regression analysis were performed with the Spotfire statis-
ical package (Spotfire, Inc, Sommerville, Mass) to illustrate tumor
esistance patterns for any given doublet pair analyzed.
Potential associations between drug resistance to a single agent
nd DNA ploidy or the molecular markers p53 and EGFR were
lso abstracted from the database with Spotfire and analyzed with
PSS software (SPSS, Inc, Chicago, Ill) by 2 testing.
esults
ingle-agent Chemotherapy Resistance Profiles
rug-resistant profiles are shown in (Figure 1) for NSCLC
umor cell cultures exposed to frequently used chemother-
py agents. The frequency of EDR ranged from 13% (202/
531) for topotecan and 13% (280/1351) for navelbine to
1% (917/1513) for gemcitabine. EDR tumors were noted
n 485 (16%) of 3042 cultures exposed to cisplatin, in 518
23%) of 2283 cultures exposed to carboplatin, in 432 b
54 The Journal of Thoracic and Cardiovascular Surgery ● Febr14%) of 3181 cultures exposed to etoposide, in 392 (16%)
f 2485 cultures exposed to taxol, in 186 (17%) of 1119
ultures exposed to docetaxel, and in 337 (22%) of 1567
ultures exposed to doxorubicin.
aired Analysis
SCLC tumor cultures assayed separately against platin
gents (cisplatin plus carboplatin) and vinca alkaloids
vincristine plus vinorelbine [Navelbine]) were analyzed
or concordant resistant patterns. For cisplatin and car-
oplatin 1099 specimens were tested separately to both
gents and showed similar distributions of drug resis-
ance (R  0.76). For the vinca alkaloids, 28 cultures
ere assayed with both agents and resistance profiles
orrelated (R  0.92) (Figure 2). Little correlation was
oted on scatter plots for the paired combinations carbo-
latin versus paclitaxel and the drug combinations tested
ith cisplatin: navelbine, docetaxel, or gemcitabine. For
523 tumors separately tested with carboplatin versus
aclitaxel (R  0.189), 80 (5%) were EDR and 393
26%) were LDR to both drugs. Combined IDR and EDR
umors were observed in 422 (28%) of the population,
nd 1130 (74%) were IDR or EDR to at least one agent
Figure 3, A). In 1314 cultures tested for cisplatin versus
avelbine (R  0.018), 32 (2%) were EDR and 418
32%) were LDR to both. Combined IDR and EDR tumor
ultures comprised 263 (20%) of the population, and 896
68%) were IDR or EDR to at least one drug (Figure 3,
). For cisplatin versus docetaxel, of 741 cultures tested
R  0.182), 35 (5%) were EDR and (32%) were LDR to
igure 1. The frequency of chemotherapy resistance for NSCLC
umor cultures exposed to cisplatin (CPLAT), carboplatin (CARBP),
toposide (VP16), paclitaxel (TAXOL), vinorelbine (NAVBL), do-
etaxel (TAXTR), and gemcitabine (GEMCB) are shown as per-
entages. Low drug resistance (LDR) is inhibition of growth 1 SD
bove the population median; intermediate drug resistance (IDR)
s inhibition between the population median and 1 SD below the
edian; and extreme drug resistant (EDR) tumors are 1 SD below
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TS02 (27%) of the population, and 507 (68%) were resis-
ant to at least one (Figure 3, C). For cisplatin versus
emcitabine, of 994 cultures tested (R  0.09), 136
14%) were EDR and 110 (11%) were LDR to both.
ombined IDR and EDR tumor cultures comprised 439
44%) of the population and 884 (89%) were resistant to
t least one (Figure 3, D).The Journal of Thoracichemotherapy Resistance and Ploidy
n association between chemotherapy resistance and
iploid versus nondiploid tumors was examined. LDR
ompared with combined IDR and EDR tumors showed
hat aneuploid tumors were more likely to be resistant to
toposide, 218 (53%) of 415 versus 59 (36%) of 167 (P
.0002), and topotecan, 177 (48%) of 369 versus 56
Figure 2. Correlation and concurrent
chemotherapy resistance illustrating
congruent patterns for NSCLC tumor
cultures exposed in separate assays to
like agents, cisplatin (CPLAT) and car-
boplatin (CARBO) (N  1099, R  0.76)
(A) or to vinblastine (VIN) and vincris-
tine (VCR) (N  28, R  0.92) (B), are
shown as percent colony inhibition
(PCI) for each drug tested. Each data
point (jittered for clarity) represents
the combined in vitro response for a
single tumor culture.
Figure 3. Concurrent chemotherapy re-
sistance patterns for NSCLC tumor cul-
tures exposed in separate assays to
one of four standard platinum-based
chemotherapy doublets. A, Carboplatin
(CARBO) and paclitaxel (TAXOL) (N 
1523, R  0.189); B, cisplatin (CPLAT)
and navelbine (NAVBL) (N  1314, R 
0.018); C, cisplatin (CPLAT) and gemcit-
abine (GMCB) (N 741, R 0.182); and
D, cisplatin (CPLAT) and docetaxel
(TAXOT) (N 994, R 0.09) are shown
for each pair as percent colony inhibi-
tion (PCI) for each drug tested. Each
data point (jittered for clarity) repre-
sents the combined in vitro response
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TS36%) of 157 (P  .0094), whereas aneuploid tumors
ere less resistant to gemcitabine, 149 (88%) of 169
ersus 317 (81%) of 392 (P  .0345). Aneuploid tumors
ere relatively less resistant to cisplatin and taxotere and
ore resistant to carboplatin, doxorubicin, taxol, and
avelbine, but differences were not statistically signifi-
ant (Table 1).
hemotherapy Resistance and Markers p53
nd EGFR
ositive versus negative p53 staining was compared with
DR versus IDR plus EDR tumors. In p53-positive tumors
ompared with p53-negative tumors, cultures were more
esistant to etoposide, 169 (57%) of 295 versus 171 (44%)
f 385 (P  .0009) and to doxorubicin, 66 (73%) of 90
ersus 53 (58%) of 91 (P  .0324). Less chemotherapy
esistance was noted in p53-positive tumors for cisplatin in
27 (44%) of 288 versus 200 (54%) of 371 (P  .0125), for
arboplatin in 136 (47%) of 288 versus 213 (57%) of 374




LDR† IDR‡  EDR§
N % N %
isplatin 76 46 91 54
arboplatin 102 53 92 47
toposide 108 65 59 35
oxorubicin 11 46 56 36
opotecan 101 64 56 36
axol 98 49 101 51
axotere 73 54 63 46
avelbine 132 73 50 27
emcitabine 20 12 149 88
P value for 2  .05 is significant. †Low drug resistance. ‡Intermediate




LDR† IDR‡  EDR§
N % N %
isplatin 171 46 200 54
arboplatin 161 43 213 57
toposide 214 56 171 44
oxorubicin 38 42 53 58
opotecan 172 55 141 45
axol 174 43 234 57
axotere 144 55 119 45
avelbine 238 67 117 33
emcitabine 44 13 283 87P value for 2  .05 is significant. †Low drug resistance. ‡Intermediate drug
56 The Journal of Thoracic and Cardiovascular Surgery ● FebrP  .0129), for taxol in 148 (47%) of 315 versus 234
57%) of 408 (P  .0056), and for gemcitabine in 185
78%) of 236 versus 283 (87%) of 327 (P  .0108). No
tatistical difference was noted for topotecan, taxotere, or
avelbine (Table 2).
LDR plus IDR versus EDR chemotherapy resistance was
ompared to low versus high EGFR histoscores, defined as the
roduct of staining intensity  the number of positively
tained cells. High EGFR histoscores were associated with
ecreased EDR for cisplatin in 23 (13%) of 183 versus 19
26%) of 72 (P  .0074), for carboplatin in 26 (13%) of 203
ersus 24 (30%) of 81 (P  .0008), and trend toward signif-
cance for topotecan in 32 (18%) of 182 versus 20 (27%) of 75
P  .0994) was noted. Increased EDR for gemcitabine was
bserved in 130 (67%) of 194 versus 40 (52%) of 77 (P 
0207) in tumors with high EGFR histoscores. No statisti-
ally significant differences were observed for etoposide,




P value*LDR IDR  EDR
N % N % 2
209 54 181 46 .0804
214 49 221 51 .4334
197 47 218 53 .0002
24 42 33 58 .7571
192 52 177 48 .0094
202 45 248 55 .3046
190 57 144 43 .5250
282 66 145 34 .1164
75 19 317 81 .0345
resistance. §Extreme drug resistance.
resistance for NSCLC of adenocarcinoma histology
IHC
p53 Positive
P value*LDR IDR  EDR
N % N % 2
161 56 127 44 .0125
152 53 136 47 .0129
126 43 169 57 .0009
24 27 66 73 .0324
109 52 99 48 .5677
167 53 148 47 .0056
114 57 85 43 .5871
186 69 82 31 .5315
51 22 185 78 .0108emo
NA prapy
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TSiscussion
n Vitro Chemotherapy Resistance Versus
hemosensitivity Testing
he clinical utility of in vitro chemotherapy sensitivity and
esistance assays to estimate clinical response to chemother-
py has been debated for nearly a decade, and in recent
ears some oncologists, having continued skepticism, may
ot fully appreciate some important historical developments
hat led to the distinction between chemosensitivity and
hemoresistance. The latest review and technology assess-
ent published by the American Association of Clinical
ncology (ASCO) is an example of recent publications that
ere considered biased and nearsighted by some, failing to
cknowledge several shortcomings of older methods and
efining salient differences between sensitivity and resis-
ance testing.15-18 Advances in cell culture technology, test
vailability, reliability, and reproducibility attest to the ro-
ust nature of some chemotherapy-resistant assays and
rompted the Medicare approval of chemotherapy resis-
ance (not sensitivity) testing.19 Two types of assays are
escribed below to illustrate differences between chemo-
herapy resistance and sensitivity.
Older clonogenic assays relied on brief exposures to
hemotherapy at or below peak serum concentrations, fre-
uently used cell culture techniques permitting growth of
tromal elements, required long incubation times, which
imited clinical usefulness, and often used inaccurate man-
al cell-counting methods. Assumptions that in vitro tumor
ensitivity equates with clinical response accounts for nei-
her tumor factors of anatomic permeability and vascularity
or host factors of absorption, metabolism, activation, or
limination.
In contrast, the EDR assay is a cellular proliferation
ssay in which tumors are exposed for 120 hours to supra-
harmacologic doses of chemotherapy up to 10-fold higher
ABLE 3. Association between EGFR and in vitro chemoth
E
gent
EGFR histoscore low <120
LDR†  IDR‡ EDR§
N % N %
isplatin 53 74 19 26
arboplatin 57 70 24 30
toposide 67 92 6 8
oxorubicin 5 71 2 29
opotecan 55 73 20 27
axol 66 79 18 21
axotere 63 94 4 6
avelbine 79 95 4 5
emcitabine 37 48 40 52
P value for 2  .05 is significant. †Low drug resistance. ‡Intermediatehan peak plasma concentrations. Stromal cell growth is c
The Journal of Thoracicnhibited by cell platting on soft agarose, and cellular pro-
iferation is reliably measured by 3H-thymidine incorpora-
ion into DNA. When the relative cellular growth of a
pecific culture is compared with well over 140,000 human
umors exposed to the same drug, tumor growth inhibition 1
D below the median inhibition identifies resistant tumors
ithout reference to clinical sensitivity. Comparing clinical
esponse to chemotherapy with an independent tumor set of
50 human tumor cell cultures, 20 of which were NSCLC,
he ability of the EDR assay to detect tumor resistance to a
articular chemotherapeutic agent was over 99% specific.7
ecently, we have rekindled an interest in the clinical ap-
lication of chemotherapy resistance assays not only to help
redict an observed response to adjuvant chemotherapy, but
n hopes of avoiding unnecessary toxicities related to po-
entially ineffective cytotoxic agents.
djuvant Chemotherapy in Resected NSCLC
nthusiasm to administer platinum-based adjuvant chemo-
herapy after complete resection of stage IB-IIIA NSCLC
as been fueled from the results of 4 randomized clinical
rials. Controversy regarding the universal application of
djuvant chemotherapy after resection of stage IB disease
ontinues. In the International Adjuvant Lung Cancer Trial
IALT), patients with stage IA-IIIA disease received cispla-
in plus etoposide (57%) or a vinca alkaloid (43%). Al-
hough an overall 4% increase in 5-year survival was noted,
nly patients with stage IIIA disease benefited. Grade 4
oxicity occurred in 24%, and non–dose dependent lethal
latinum toxicity occurred in up to 2.4% of patients.2
Both the National Cancer Institute of Canada Clinical
rial Group–JBR.10 trial and the Adjuvant Navelbine In-
ernational Trialist Association (ANITA) trial used the cis-
latin plus vinorelbine doublet for adjuvant therapy after
y resistance for NSCLC of adenocarcinoma histology
y IHC
EGFR histoscore high > 120
P value*LDR  IDR EDR
N % N % 2
160 87 23 13 .0074
177 87 26 13 .0008
160 87 24 13 .2774
11 79 3 21 .7171
150 82 32 18 .0994
167 82 37 18 .5183
163 92 15 8 .5216
178 91 17 9 .2603
64 33 130 67 .0207
resistance. §Extreme drug resistance.erap
GFR bomplete resection. JBR.10 included patients with stages
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TSB-II disease, but a survival benefit occurred only in patients
ith stage II disease. Grade 3 or 4 neutropenia occurred in
3% of patients in the chemotherapy arm. In the ANITA
rial, survival advantage with adjuvant chemotherapy was
oted for patients with stage II-IIIA disease, but no ob-
erved survival benefit was noted in patients with stage IB
isease.4,5
The Cancer and Leukemia Group B (CALGB)– 9633
rial randomized only patients with stage IB (T2 N0) disease
ither to adjuvant carboplatin plus paclitaxel or to observa-
ion alone after complete resection. These data, presented in
bstract form at ASCO in 2005, are yet to be published
therwise. They reported an improvement in overall sur-
ival among the adjuvant chemotherapy patient arm of the
tudy of 12% at 4 years’ follow-up. Grade 4 neutropenia
ccurred in 36%, and 45% of patients either did not com-
lete therapy or required dose reductions. This recent trial is
lone in reporting a demonstrable survival benefit for adju-
ant chemotherapy in patients with stage IB disease.3 Sub-
equent reanalysis of the data from this trial suggests that
he study design was underpowered to definitely suggest a
ong-term survival benefit of adjuvant chemotherapy for
tage IB disease.20 These more recent findings provoke
ontinued skepticism with the utility of presently available
mpiric adjuvant chemotherapy for completely resected
tage IB disease.
ultiple Drug Chemotherapy Resistance
n this study, the resistance of NSCLC tumor cultures ex-
osed to several individual chemotherapy agents of clinical
elevance was analyzed. The results are consistent with our
reviously reported prevalence of chemotherapy resistance
n both NCSLC tumor cultures11 and other solid tumors.14,21
espite potential limitations of not exposing tumors to two
rugs simultaneously to test for chemotherapeutic agent
ynergy, these data illustrate that tumors are frequently
esistant to at least one agent in chemotherapy doublet
egimens commonly used throughout North America and
urope today. Even though the frequency of tumors exhib-
ting extreme chemotherapy resistance to both agents is less
mpressive, the frequency of extreme or intermediate resis-
ance to at least one chosen agent is alarmingly high, sug-
esting that patients may benefit from only one drug with
mpiric “doublet chemotherapy” selection. Accordingly,
ehta and associates8 examined this phenomenon in breast
ancer and found that the median time to disease progres-
ion and survival was significantly shorter for patients
reated with any combination of agents exhibiting either
xtreme or intermediate in vitro drug resistance in compar-
son with patients having tumors with low in vitro resistance
o both drugs. In vitro drug resistance correlated with a
horter survival similar to that associated with advanced
tage or positive lymph node status. It is interesting to note c
58 The Journal of Thoracic and Cardiovascular Surgery ● Febrhat in our study, tumor resistance observed in doublet
nalysis is in parallel with the observed clinical response
eported in the JBR.10 and ANITA trials, where the greatest
urvival advantage is reported with the cisplatin plus vi-
orelbine doublet.4,5
NA Ploidy, Molecular Markers, and Chemotherapy
esistance
e report an association between tumor chemotherapy re-
istance and DNA ploidy for some antineoplastic agents.
neuploid tumors were likely to be less resistant to gem-
itabine, yet were more resistant to etoposide and topotecan.
he potential clinical relevance of this association for these
rugs is interesting but obscure. Other investigators have
lso identified a possible relationship between tumor ploidy
nd chemotherapy resistance. Doubre and associates22 re-
orted a 3-fold increase in levels of multiple drug resistance
rotein (MDR1) in 84 previously untreated aneuploid
SCLC tumors and found that DNA aneuploidy resulted
rom an increased gain of chromosome 16 where the MDR1
ene is located. Volm and colleagues23 analyzed 240 pa-
ients with NSCLC having aneuploid tumors with more than
ne stem line. In vitro chemotherapy resistance was asso-
iated with an observed decreased survival in patients un-
ergoing chemotherapy having aneuploid tumors compared
ith patients with diploid and in vitro sensitive tumors.
Our investigation has also identified a possible associa-
ion between p53 expression and chemotherapy drug resis-
ance. We found that p53-positive tumors were more often
ess resistant to cisplatin, carboplatin, paclitaxel, and gem-
itabine, but were more often associated with increased
esistance to etoposide and doxorubicin. This association
or cisplatin in vitro resistance in p53-positive tumors is
nconsistent with clinical results from others24,25 in which
6% patients with p53-positive tumors in chemotherapy
aive advanced NSCLC responded to cisplatin versus 57%
f patients with p53-negative tumors. This discrepancy may
e related to the ability of suprapharmacologic doses of
ome chemotherapeutic agents to overcome the suppressor
ene checkpoint imparted by p53. Interestingly, d’Amico
nd coworkers26 showed that female patients with stage I
ung cancer and p53-positive tumors had a decreased sur-
ival of 49% compared with 77% of women with p53-
egative tumors.
Increasing interest in the prognostic importance of EGFR
xpression related to targeted therapy for NSCLC stimu-
ated us to examine this molecular marker with regard to
esistance to “standard” chemotherapy agents for this dis-
ase. Onn and associates27 reported a trend toward de-
reased survival from 84.4 months to 44.2 months among
11 patients with stage 1 NSCLC who had synchronous
xpression of EGFR and the HER2-neu protein. The finding
f EGFR gene polymorphisms measured by polymerase
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TSvaluated in advanced colorectal cancer and has been found
o be associated with an increased likelihood of disease
rogression with 5-fluorouracil/oxaliplatin chemotherapy
hen the increased gene copy number was identified.28
bservations from our study revealed that increased EGFR
xpression, measured by immunohistochemistry, is associ-
ted with a decreased in vitro resistance to platinum agents
nd increased in vitro resistance to gemcitabine. Our study
acks clinical correlation and distinction between EGFR
xpression levels, the presence of specific mutations deter-
ined by polymerase chain reaction, or measurements of
ene copy number by florescent in situ hybridization. Com-
arisons of these assay modalities may warrant additional
tudy. Further analysis of associations between EGFR and
hemotherapy resistance should be considered for early-
tage patients based on the decreased survival noted for
GFR-positive tumors in patients with stage I disease.27
he Cellular Proliferation Chemotherapy Resistance
ssay and the Relationship to the Cancer Stem
ell Hypothesis
n regeneration of normal (nontransformed) tissue, quies-
ent stem cells are activated to enter the cell cycle and the
ormation of new replacement tissue occurs in response to
nvironmental stress. The cancer stem cell hypothesis states
hat the cancer-initiating cell is a transformed tissue stem
ell, which retains the essential property of self-renewal
hrough the activity of MDR transporters.29 In normal tis-
ue, the genetic regeneration program is turned off after
issue restoration once homeostasis is restored. Unlike nor-
al tissues, homeostasis in progenitor cancer cells is abnor-
al. Thus, tumor cells can overcome anticancer therapy not
nly by the activation of mechanisms specific for trans-
ormed cells, but also by taking advantage of a normal tissue
egeneration genetic program.30
Human tumors are composed of nonhomogeneous cell
opulations including cancer stem cells and transformed
rogenitor cells. These heterogeneous populations are all
epresented in cell culture conditions used in the EDR assay
nd include subpopulations of cancer stem cells that con-
titutively express the MDR phenotype and are inherently
hemotherapy resistant. An example of how the EDR assay
an predict clinical chemotherapy resistance and may be
elated to the proliferation of cancer stem cells is noted in a
tudy of breast cancer tumor cultures that exhibited an in
itro chemotherapy resistance to both paclitaxel and doxo-
ubicin.14 Overall, MDR1 P-glycoprotein expression was
hown to occur in 17% of these patients’ tumors. When
urther stratified, tumors from chemotherapy naive patients
howed an 11% incidence of MDR1 expression compared
ith a 30% incidence of MDR1 expression in tumors from
reviously treated patients. The clinical response to
oxorubicin and paclitaxel was lower in the previously (
The Journal of Thoracicreated MDR1-positive groups than in the untreated MDR1-
egative groups.14
It should be noted that tumors might possess in vitro drug
ensitivity because of an agents’ anticancer activity or might
xhibit resistance because of the tumors’ phenotypic resis-
ance to the agent. In the EDR assay, some agents may
vercome unfavorable cellular transport kinetics or perme-
bility barriers because of high drug concentration gradients
hat favor intracellular drug accumulation. These cells may
xhibit in vitro sensitivity even if they are inherently resis-
ant stem cells. This relates clinically to anticancer therapy
nd the cancer stem cell hypothesis where an agent might
liminate the main population (non-stem) cells, resulting in
election of cancer stem cells. It follows that transformation
f this small population of cancer stem cells might ulti-
ately result in clinical tumor progression, recurrence, or
etastatic disease. A priori, a potential limitation of the
bility of cellular proliferation assays to accurately predict
linical sensitivity, other than patient host factors, may be
ue to a relatively decreased potential for a small population
f cancer stem cells to proliferate significantly relative to
ther tumor cells under tissue culture conditions of the EDR
ssay. Further studies on the relationship between in vitro
hemotherapy resistance testing as it relates to the cancer
tem cell hypothesis are ongoing.
andomized Trials and the Clinical Utility of
hemoresistance Testing
e11 previously reported that extreme or intermediate in
itro chemotherapy resistance in NSCLC patient tumor
ultures was prevalent, particularly for platinum agents
63%–68%) and for gemcitabine (72%). From the analysis
f a larger database representing 4571 NSCLC fresh tumor
ultures in this study, the incidence of resistance to platinum
gents (62%–63%) and gemcitabine (80%) was similar.
ore important, we frequently found that many tumors
xhibited simultaneous resistance to both agents used in
our of the most commonly prescribed platinum-based che-
otherapy doublets. These results raise concern regarding
he widespread use of empiric adjuvant chemotherapy,
here few patients may benefit, and in particular, conster-
ation exists with the recommendation of adjuvant chemo-
herapy to patients with completely resected stage IB dis-
ase in whom a survival advantage is questionable.20
In patients with stage IV NSCLC, a randomized clinical
rial by the Eastern Cooperative Oncology Group (ECOG)
ompared overall survival in patients treated with cisplatin
lus gemcitabine, cisplatin plus docetaxel, or cisplatin plus
aclitaxel in reference to the efficacy of carboplatin plus
aclitaxel. An overall 19% response rate and median sur-
ival of 7.9 months was observed with 1-year and 2-year
urvivals of 33% and 11%, respectively. Neither response
ates nor survival differed significantly with any regimen
Figure 4). Schiller and associates31 concluded that none of
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TShe four regimens offered a significant advantage over the
thers, yet the carboplatin plus paclitaxel doublet was cho-
en as the ECOG reference for future studies because of
educed toxicity. On the basis of these data showing similar
linical efficacy among several regimens, empiric selection
f any doublet combination is without significant predict-
ble value to the patient with regard to “doublet” efficacy.
he application of tumor chemotherapy resistance testing
herefore may be of clinical benefit.
Chemoresistance testing may help select a second drug
or a platinum-based doublet by “deselecting” one agent on
he basis of its in vitro chemotherapy resistance. Patients
ith metastatic disease and those undergoing “salvage”
herapy may benefit most from chemotherapy deselection
hen one or more agents are considered, perhaps avoiding
nnecessary toxicity from ineffective second- or third-line
herapies.
Despite the intriguing possibilities of using chemoresis-
igure 4. Kaplan–Meier estimates of overall survival (A) and the
ime to progression of disease (B) in the ECOG study patients
nrolled according to their assigned treatment (From Schiller JH,
arrington D, Belani CP, Langer C, Sandler A, Krook J, et al.
omparison of four chemotherapy regimens for advanced non–
mall-cell lung cancer. N Engl J Med. 2002;346:92-8. Reprinted by
ermission of the Massachusetts Medical Society. Copyright 2002
assachusetts Medical Society. All rights reserved).ance testing to improve response and reduce toxicity re- o
60 The Journal of Thoracic and Cardiovascular Surgery ● Febrated to therapy, its use for the purpose of “assay directed”
reatment is currently lacking clinical validation in NSCLC.
he recent ASCO technology assessment15 has recom-
ended that future studies be designed comparing empiric
hemotherapy with resistance assay–directed chemother-
py. Despite these recommendations, it has been empha-
ized that despite the availability and reliability of chemo-
herapy resistance testing, the general medical oncology
ommunity has yet to integrate this concept into any coop-
rative group trial.18 In Weiands’ rebuttal32 to this ASCO
eport, he suggests that the clinical utility of resistance
esting be validated in a single-arm, noninterventional assay
ccuracy trial using two or more therapies known to have
imilar response rates to determine whether the assay is
redictive of response. We agree with Weiand’s assessment
f this concept and would support such as trial for NSCLC.
Validation of the clinical utility of the EDR assay may be
est achieved by correlating in vitro resistance to clinical
utcome in patients considered for adjuvant chemotherapy
ho are eligible for enrollment in an existing adjuvant
hemotherapy trial, or as a companion to a surgical trial
ith an adjuvant chemotherapy arm. The recently proposed
COG 1505 phase III trial will randomize 1500 eligible
atients with resected stage IB-IIIA NSCLC to adjuvant
hemotherapy with the four most accepted platinum-based
doublets” with or with out bevacizumab. Drug resistance
esting is well suited as a companion to this trial, irrespec-
ive of a potential bevacizumab response.
Recently, members at Duke University developed a
enomic strategy to estimate prognosis in patients with
esected stage I NSCLC using RNA micro array analysis.
y developing a multiple gene expression profile, they
reated a lung metagene model and validated it with two
ndependent tumor sets. The prognostic accuracy to predict
ecurrence and survival approached 90%.33 These results
ave prompted the development of a CALGB trial designed
o prospectively validate the lung metagene models’ ability
o differentiate low-risk from high-risk patients. Patients
ith completely resected stage IA NSCLC will be separated
n a 1:2 ratio into a low-risk (observation only) group and
igh-risk group. High-risk patients will then be randomized
o receive one of the four NSCLC adjuvant chemotherapy
oublet regimens (similar to those proposed for ECOG
505) or observation alone. Although this model may help
istinguish between patients with a favorable prognosis who
nly require observation, half of the high-risk patients will
e prescribed cytotoxic chemotherapy with an uncertain
enefit. Despite these efforts to “target” therapy based on
rognosis, empiric adjuvant chemotherapy is still applied in
his study. Clinical observations of recurrence and survival
n the high-risk patient arm, if correlated with chemotherapy
esistance testing, may help further define the clinical utility
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G
TSAs the public continues to cry out to “wage the war on
ancer,”34 identifying genomic profiles that predict progno-
is, and using molecular marker assays to predict therapeu-
ic response, developing clinically relevant studies for more
elective therapies will become increasingly important. In-
egrating molecular testing and chemotherapy resistance
ssays into future adjuvant chemotherapy trials for NSCLC
ill facilitate avoiding yet another decade of pure empiri-
ism in patient care. This paradigm shift appears necessary
nd justified.
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iscussion
r David M. Jablons (San Francisco, Calif). It is a pleasure to
eview this paper. I have only a few questions and some observa-
ions.
What we have heard here this morning, or at least what is in the
anuscript, is a retrospective analysis of a large, prospectively gath-
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TSred sample of patients with early-stage resected NSCLC for the
urpose of assaying in a primary cell culture system—remember, on
gar—chemotherapy resistance, not sensitivity. It is an impressive
xperience over many years. More than 4500 fresh tumor samples
ere submitted to a commercial entity, Oncotech, Inc, which is a
or-profit organization, for chemoresistance testing and ultimately
ecently gene analysis. This a reimbursable test currently that has
ained some but not universal acceptance. An important distinc-
ion was brought up in the talk and needs to be reinforced: these
ssays are chemoresistance and not chemosensitivity, and as such
he authors argue are more “credible” and more predictive of
linical response. It may be that they are right, but certainly no
ssessment can be made from the dataset presented today. I would
gree to a certain extent that a tritium proliferation assay in a
ong-term culture of 5 days on agar is perhaps more quantifiable
nd may be more accurate. Perhaps the advantage of having a
rude tumor preparation where you have a lack of tumor cell
solation and you have no macrodissection or microdissection can
ither be a good or a bad approach, in my opinion. It is good in the
ense that it is more representative of the actual tumor perhaps in
ts milieu with stromal cells and vascular cells and immune cells
nd maybe the purported cancer stem cells. Yet it may be that the
ack of tumor cell isolation allows or accounts for why this high
hemoresistance is observed. Remember that these cells are being
ultured, as I understood from the paper, in very high supraphysi-
logic concentrations of chemotoxic agents, 10-fold to 100-fold
igher, which are at least 2 to 3 log orders higher than they would
ver see in the microenvironment in vivo. So one quick question
hat comes to mind is, did these resistance patterns vary at all with
istology? For instance, there is no comment in the paper that there
as an association with adenocarcinoma versus squamous, subsets
f adenocarcinomas that we know are notoriously more chemore-
istant—for example, neuroendocrine, large cell, bronchoalveolar.
as there any attempt at Oncotech or otherwise to classify that?
lso, in the molecular analysis, was there any microdissection of
he tumors, because without that there is no way to safely contend
r conclude that what you are measuring is really tumor focus.
inally, what was the FedEx factor in this? We have all done these
xperiments and sent our samples, and I am curious there is no
omment as to the overall success rate. Having been in the gene
accine business for a long time, we were surprised that we could
et 80% viability shipping tumor samples for fresh autologous
accines across country, so how was it in this? Finally, how
ealistic is this assay? The answer, in my opinion, is not very.
espite the many objections and the artifactual-ness of the assay,
t has been shown as represented in the paper in several other
umor systems, ovarian and breast cancer, to have some prognostic
ctivity and validity. So I would ask the authors, who are busy
linicians and have a large thoracic surgery and lung cancer
ractice—this has not been validated prospectively and needs to
e, I agree—what have you been doing either off study or on study
n small pilot studies in your institution to validate this? Do you
se this as a proponent of this therapy, because it is highly
ontroversial in this assay? Do you personally use it to guide
herapy? If not, why not?
In the interest of time, I will limit the comments regarding stage
B adjuvant chemotherapy. I think it can be safely concluded now,
nd Eric is in the back and can concur, at ASCO just a few weeks a
62 The Journal of Thoracic and Cardiovascular Surgery ● Febrgo the analysis of the CALGB data is now a negative trial. The
arger trials and more robust longer follow-up trials, ANITA,
ALT, and others, showed no benefit for adjuvant platinum-based
hemotherapy in patients with stage 1B disease that are node
egative. So I no longer believe that is standard of care. There are
any issues with the molecular analysis of p53. It is only one
ene. It is notoriously inaccurate by immunohistochemistry. And
14, MDM2, there are lots of way to skin that gene, and when you
ust look for immunohistochemistry, it is very unpredictable and
nreliable.
In light of the impending revolution in molecular classification
nd fingerprinting of tumors and emergence of novel targeted
herapies and agents, just keep in mind that there are nearly 300
ew agents, not to mention Irv [Dr Irving Weismann]’s 300-odd
ompanies I’m sure, that are coming into clinical testing in the next
to 5 years. Is there a role in this day and age for the “old world”
hemotherapy and a reason to believe that in vitro chemoresistance
esting can be useful to select efficacious agents? Molecular anal-
sis is sexy and exciting and is, remember, mostly prognostic at
his point, but not therapeutic. So in the next 3 to 5 years, perhaps
onger, chemotoxic, cytotoxic chemotherapy is here to stay.
s such, anything, if validated prospectively, that can direct
nselected empiric therapy to select patient populations and their
umors would be a meaningful advance. As the saying goes, in the
and of the blind, the one eye is king. The time is ripe to test this
nd other in vitro chemoresistance assays for clinical response and
urvival as their end points. This is yet to be done in NSCLC.
It is time to put the assay to the real “test” road and design an
djuvant trial for the intergroup that has drug selection based on
ome form of rational in vitro testing as a basis, and only then can
e determine whether this is a valid approach.
Dr d’Amato. Thank you, Dr Jablons. I’ll try to address as
any of your questions as I can.
Currently, it is difficult to get many of the medical oncologists
o treat patients based on this assay. We do have several at the
niversity of Pittsburgh who will, and when I was in practice in
outhern California, I had several who would treat people based on
he assay. I put forward a proposal to the CALGB last year to use
he assay as a validation trial, as a single arm, nontreatment trial
hat would serve to validate the assay. The problem with an
ssay-directed versus empiric trial obviously is that that would
reate a subset of patients in whom you would eliminate plat-
num. Because that has been the standard of care for NSCLC,
liminating a platinum agent if a patient were resistant would be
eyond that, so a clinical validation, at least for the resectable
isease, is important. Those proposals are being put forth to the
ntergroup.
Regarding the assay and the mechanics of the assay, some-
here between 75% and 85%, what we call a valuability,
eaning viable tumor cells that can be cultured, arrived by
edEx when the tumors were prepared properly and sent and
id not sit on a loading dock. There are extremes from that, I’m
ure, as you have seen in your own experience with the vaccine
ork.
Stromal cells and vascular endothelial cells are inhibited in the
ssay conditions on agarose and this has been well established for
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TSow to culture tumor cells in the older (clonagenic) assays, so I
on’t believe that right now is a particular issue.
There are some differences between the frequencies of in vitro
esistance to chemotherapeutic agents in non–small cell tumor
ultures of different histology. For example, as we may expect
rom clinical observations, NSCLC tumors having bronchoalveo-
ar histology appear to exhibit more in vitro resistance to most
gents. These data are currently being analyzed and have yet to be
alidated. n
The Journal of ThoracicRegarding micro dissection, this is not performed for standard
mmunohistochemistry.
I believe that the molecular markers that we have chosen are
ifficult to assess in terms of the resistance assay. I also agree that the
mmunohistochemistry as end point measurements are not as accu-
ate, particularly with EGFR. The missing link here with these mark-
rs is the clinical data. Finding associations is interesting, but are they
eaningful? As you have noted, in the manuscript they probably areot meaningful in this context without clinical validation.
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